Watson CEO Seeks Brand-Drug Profits in Shift From Copycats

Watson Pharmaceuticals Inc. Chief Executive Officer Paul Bisaro is looking to acquire brand-name drug assets and make a future “‘transformational” purchase as he reshapes the generic-drug maker.

Bisaro, 51, said in an interview he wants to use an estimated $6 billion the company will have available for acquisitions to invest in brand-name medicines with the potential for greater growth and consistent returns. Watson will consider drugs for gender-specific conditions as it builds toward a “big brand deal” to supplement its generic lines.